# Myeloprotection With Trilaciclib in Pan-cancer Population

> **NCT06297811** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 132 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Breast Cancer
- Endometrial Cancer
- Cervical Cancer
- Head And Neck Squamous Cell Carcinomas

## Interventions

- **DRUG:** Trilaciclib Injection
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06297811
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297811, "Myeloprotection With Trilaciclib in Pan-cancer Population". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06297811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*